Share this @internewscast.com

The Food and Drug Administration approved a request by Eli Lilly on Wednesday to begin marketing its tirzepatide medication, which is branded as Mounjaro for diabetes, under a new brand for weight loss as well.

While Mounjaro had already been used by some patients “off-label” for weight loss, the new FDA approval will allow the drugmaker to begin officially selling and marketing tirzepatide — branded as Zepbound — for weight loss too.

Zepbound will be available for patients in the U.S. by the end of the year, the drugmaker said.

The company said Wednesday in a news release that the medication, administered with an injection pen, will be sold at a cheaper list price than its semaglutide competitors from Novo Nordisk, which are branded as Wegovy for weight loss and Ozempic for diabetes. 

“New treatment options bring hope to the many people with obesity who struggle with this disease and are seeking better options for weight management,” Joe Nadglowski, CEO of the Obesity Action Coalition, said in Eli Lilly’s release. The group receives funding from Eli Lilly and other pharmaceutical and health care companies.

The FDA’s approval of Zepbound was partially based on a trial of adults without diabetes, which found that participants — who averaged 231 pounds at the start of the trial — who were given the highest approved dose lost around 18% of their body weight compared to placebo.

zepbound.jpg
The FDA approved Eli Lilly’s drug Zepbound for weight loss.

Eli Lilly


“In light of increasing rates of both obesity and overweight in the United States, today’s approval addresses an unmet medical need,” the FDA’s Dr. John Sharretts, director of the agency’s Division of Diabetes, Lipid Disorders, and Obesity, said in a news release.

While there have not been results from large clinical trials comparing Novo Nordisk’s and Eli Lilly’s medications head-to-head, there is some research to suggest Zepboud could outperform Ozempic

A meta-analysis presented at the annual meeting of the European Association for the Study of Diabetes in October concluded tirzepatide was “more effective for weight loss than semaglutide, with a larger weight-loss effect at higher doses,” but acknowledged limitations in trying to make a direct comparisons of the two.

In a report earlier this year comparing semaglutide and tirzepatide for diabetics, the Institute for Clinical and Economic Review concluded that tirzepatide showed “greater reduction” in weight and other key markers, but “had a greater incidence of gastrointestinal side effects, severe adverse events, and discontinuation compared with semaglutide.”

Zepbound carries the risk of an array of potential side effects, the FDA says, including nausea, diarrhea, vomiting, constipation, and hair loss. 

Like with other weight loss drugs in this class, some of Zepbound’s side effects could be serious.  

People with a history of severe gastroparesis, or stomach paralysis, should not use the drug, the FDA says. 

Eli Lilly and Novo Nordisk have both faced claims that their drugs can cause stomach paralysis. The FDA recently moved to acknowledge reports of ileus, or a blockage in the intestines, on Ozempic’s label.

The agency also notes that other people could be at higher risk of more severe issues from Zepbound, including patients with a history of medullary thyroid cancer, pancreas inflammation, or severe gastrointestinal disease.

It also should not be combined with other so-called GLP-1 receptor agonist drugs, which include its sibling Mounjaro, as well as Wegovy and Ozempic. 

“The safety and effectiveness of coadministration of Zepbound with other medications for weight management have not been established,” the agency says.

Share this @internewscast.com
You May Also Like

Tesco Issues Urgent Recall of Gluten-Free Breadcrumbs Over Wheat Contamination Concerns

Tesco has announced a recall of its gluten-free white breadcrumbs due to…

Jill Scott Opens Up About Challenges in Sports, Highlights Key Barriers Facing Women Athletes

In a recent survey, it was revealed that 64% of women have…

Unveiling the Truth: Surprising Facts About Your Immune System You Didn’t Know

You’ve likely heard that gulping down vitamin C can fend off a…

Urgent FDA Recall: Popular Rice Brand Found Contaminated with Stones – Consumer Alert!

A well-known grocery brand has initiated a recall of several popular products…

Unexpected Menopause Symptom Revealed: The Surprising Impact on Health

Every year, approximately 1.3 million women in the United States transition into…

UK Aid Cuts Risk 300,000 Preventable Deaths, Warn Charities

Anticipation is mounting in the UK as it prepares to reduce its…

Department of Health Issues Urgent Advisory for Individuals Born in Specific Years

Young people have been warned of the dangers of these drugs that…

Eye Movements May Predict Serious Health Conditions Years Before Symptoms Emerge

Eye-tracking technology may offer a more affordable alternative for detecting a genetic…

26-Year-Old Woman Highlights Key Bowel Cancer Symptoms She Wishes She Had Recognized

A 26-year-old woman undergoing chemotherapy for bowel cancer is urging everyone to…

Unlocking the Truth: NHS GP Reveals the Real Effectiveness of the Flu Jab

As the colder months approach, the inevitable cold and flu season is…